compon
prepar
whole
blood
ml
collect
screen
unpaid
volunt
store
ml
cpd
accord
german
blood
separ
red
blood
cell
rbc
plasma
buffi
coat
standard
blood
bank
procedur
plasma
unit
leukoreduc
filtrat
plasmaflex
macopharma
pool
split
store
use
pc
prepar
pool
five
buffi
coat
describ
eriksson
pool
mix
ml
pa
ssp
macopharma
equival
suspens
centrifug
minut
g
pc
isol
leukoreduc
filter
system
autostop
bc
haemonet
store
agit
platelet
plt
concentr
approxim
plasma
content
approxim
residu
white
blood
cell
wbc
content
per
unit
air
routin
remov
plasma
unit
pc
immunosorb
assay
igg
euroimmun
use
screen
pc
plasma
unit
presenc
antibodi
product
test
antibodi
confirm
neg
use
inactiv
experi
plt
treat
use
theraflex
pi
system
consist
uvc
illumin
devic
macotron
macopharma
dispos
set
ref
xuv
xu
macopharma
briefli
pc
irradi
uvc
light
wavelength
nm
total
dose
vigor
agit
ensur
uniform
treatment
amount
uvc
energi
deliv
express
plasma
unit
use
theraflex
macopharma
pi
system
consist
theraflex
kit
macotron
illumin
devic
system
contain
mb
pill
deliv
mb
per
unit
plasma
approxim
per
plasma
unit
standard
treatment
cycl
includ
initi
filtrat
leukoreduct
plasmaflex
filter
follow
second
postillumin
filtrat
step
remov
mb
photoproduct
blueflex
filter
plasma
process
pi
efficaci
test
deviat
standard
procedur
remov
mb
photoproduct
blueflex
filtrat
perform
exclus
determin
viru
inactiv
effect
illumin
amount
light
energi
deliv
express
total
illumin
dose
set
routin
recommend
vero
cell
atcc
togeth
zair
ebolaviru
strain
grown
approxim
confluenc
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
mmoll
mgml
streptomycin
iuml
penicillin
day
viral
supernat
collect
centrifug
aliquot
frozen
use
spike
experi
vero
cell
atcc
togeth
obtain
ron
fouchier
grown
approxim
confluenc
dmem
fb
mmoll
mgml
streptomycin
iuml
penicillin
day
viral
supernat
collect
centrifug
aliquot
frozen
use
spike
experi
viru
two
bag
pc
volum
ml
plasma
volum
ml
spike
viral
supernat
treat
describ
uvc
mblight
respect
treatment
deliv
increment
full
light
dose
uvc
mblight
differ
process
step
sampl
collect
viru
titrat
perform
refer
sampl
taken
bag
treatment
store
room
temperatur
test
end
experi
account
intrins
viru
inactiv
blood
product
viru
titer
spike
expect
dilut
factor
six
eight
blood
unit
use
one
pc
one
plasma
unit
use
ebov
inactiv
four
blood
unit
use
inactiv
viru
titer
pi
treatment
log
lower
expect
dilut
howev
addit
reduct
viru
titer
observ
cours
experi
result
infect
assay
demonstr
uvc
irradi
inactiv
ebov
pc
tabl
full
uvc
dose
ebov
infect
level
detect
limit
result
viru
reduct
factor
greater
ebov
greater
mblight
effect
inactiv
ebov
plasma
unit
shown
tabl
light
dose
low
standard
full
light
dose
illumin
inactiv
ebov
plasma
level
detect
limit
result
correspond
least
least
log
reduct
ebov
respect
theraflex
theraflex
system
design
inactiv
remov
pathogen
plt
plasma
product
demonstr
wide
rang
pathogen
mechan
theraflex
shortwav
uvc
light
penetr
blood
fluid
cell
membran
caus
direct
coval
damag
nucleic
acid
pathogen
wbc
mechan
action
broadli
effect
extracellular
intracellular
pathogen
virus
bacteria
protozoa
theraflex
combin
phenothiazin
compound
intercal
viral
nucleic
visibl
light
illumin
plasma
result
gener
singlet
oxygen
lead
destruct
viral
nucleic
acid
thu
prevent
viral
mb
partial
penetr
cell
membran
mblight
treatment
less
effect
intracellular
virus
two
filter
integr
process
chain
although
second
filter
mainli
remov
mb
photoactiv
product
illumin
filter
multipl
layer
membran
capabl
remov
residu
wbc
rbc
plt
may
carri
intracellular
pathogen
recent
shown
two
filter
effici
remov
high
level
log
unit
per
millilit
viabl
bacteria
bacteri
assum
parasit
similar
size
also
remov
theraflex
procedur
previou
investig
show
filtrat
step
addit
mb
visibl
light
illumin
critic
achiev
complet
reproduc
elimin
trypanosoma
cruzi
caus
agent
chaga
estim
known
human
pathogen
consid
emerg
abil
provid
proactiv
protect
emerg
infecti
agent
complementari
exist
blood
screen
program
major
addit
benefit
pi
system
blood
safeti
thu
imper
manufactur
continu
challeng
pi
system
new
infecti
agent
knowledg
first
studi
investig
efficaci
uvc
mblight
ebov
member
coronavirida
filovirida
famili
result
show
two
pi
system
reduc
ebov
titer
limit
detect
two
blood
unit
test
maximum
viral
titer
reduct
detect
cell
cultur
infect
assay
base
start
viral
concentr
blood
product
detect
limit
assay
turn
determin
suscept
cell
cultur
plasma
plt
suspens
previou
studi
observ
reduct
ebov
titer
titer
present
studi
beyond
expect
dilut
factor
pc
phenomenon
may
occur
due
presenc
nonspecif
immun
mediat
neutral
virus
mean
log
reduct
factor
least
least
ebov
pc
treat
uvc
least
least
ebov
plasma
treat
mblight
suggest
pi
technolog
use
studi
consider
effect
two
viru
type
studi
number
limit
exampl
number
replic
limit
safeti
constraint
experi
ebov
subject
highest
biosafeti
level
addit
plate
could
perform
although
would
improv
detect
limit
enabl
exact
determin
log
reduct
factor
although
plasma
viral
rna
load
patient
may
log
genom
copiesml
median
viral
rna
load
log
genom
copiesml
detect
blood
ebola
viru
titer
plasma
asymptomat
infect
convalesc
individu
recruit
donat
blood
may
significantli
lower
known
infecti
diseas
ebov
viral
titer
express
genom
copi
per
millilit
necessarili
reflect
infect
titer
viral
titer
measur
quantit
polymeras
chain
reaction
base
detect
small
fragment
viral
genom
infect
titer
describ
number
intact
function
viral
unit
requir
replic
diseas
transmiss
although
ebov
highli
infecti
low
dose
less
unit
viru
suffici
caus
abil
system
reduc
ebov
infect
blood
product
sever
log
step
may
suffici
elimin
significantli
reduc
risk
transmiss
via
transfus
pc
plasma
conclus
studi
expand
list
pathogen
theraflex
theraflex
effect
inactiv
pc
plasma
respect
ft
sr
employe
macopharma
manufactur
distributor
theraflex
technolog
pi
ug
wh
thm
receiv
project
grant
forschungsgemeinschaft
der
ev
macopharma
develop
pi
technolog
platelet
author
disclos
conflict
interest
